DSM Pharmaceutical Products has signed a commercial agreement with a major pharma company for contract manufacturing services using its proprietary XD high cell density process technology.

Karen King, president of DSM Biologics, commented, “We are proud to announce that a major pharma company has chosen DSM’s services and technology for three of their leading antibody pipeline projects for different indications. We will apply our XD technology in combination with our technology portfolio, and manufacture from our Groningen, The Netherlands, and Brisbane, Australia facilities.”

According to DSM, XD technology is “a highly intensified cell culture process with titer achievement 5-to-15 times higher compared to current standard biomanufacturing processes.” The company notes that it is “widely applicable for multiple products including proteins, fusion proteins and antibodies, and has been successfully employed across the full spectrum of mammalian cell systems.”

DSM will complete the process development and commercial manufacturing for the products. These projects will be performed at the R&D and manufacturing site in Groningen and at new operations in Brisbane. The commercial demand will be met from Brisbane on a 500-L XD production line. Financial terms were not disclosed.